CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 69 enrolled
Drug / intervention
Bifidobacterium Animalis Oral Product +3 moredrug
Likely dose
Amoxicillin Oral Tablet 50mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03165253
NCT03165253N/ACompleted

The Effects of the Synbiotic "Bifidobacterium Lactis B94 Plus Inulin" Addition on Standard Triple Therapy of Helicobacter Pylori Eradication in Children

Bulent Ecevit University·interventional·Posted May 24, 2017·Updated May 24, 2017

In Brief

A clinical study evaluating Bifidobacterium Animalis Oral Product, Amoxicillin Oral Tablet, and 2 other interventions for Helicobacter Pylori Infection. Completed, enrolled 69 participants.

Detailed Summary

The aim of the study is to evaluate the effects of the synbiotic Bifidobacterium animalis ssp. lactis B94 plus inulin addition to the standard triple therapy on Helicobacter pylori infection eradication rates in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2017
Enrollment StartJun 1, 2011
Primary CompletionJun 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 9.1 years ago

Interventions

Bifidobacterium Animalis Oral Productdrug

The synbiotic group will receive this product.

Amoxicillin Oral Tabletdrug

50mg/kg/day B.I.D.

Clarithromycin Oral Tabletdrug

15 mg/kg/day B.I.D.

Omeprazoledrug

1 mg/kg/day